Mostrar el registro sencillo del ítem
dc.contributor.author | Ibarra-Meneses, Ana Victoria | |
dc.contributor.author | Carrillo, Eugenia | |
dc.contributor.author | Sánchez, C | |
dc.contributor.author | García-Martínez, J | |
dc.contributor.author | López Lacomba, D | |
dc.contributor.author | San Martín, Juan Víctor | |
dc.contributor.author | Alves, F | |
dc.contributor.author | Alvar, Jorge | |
dc.contributor.author | Moreno, Javier | |
dc.date.accessioned | 2020-06-08T07:39:07Z | |
dc.date.available | 2020-06-08T07:39:07Z | |
dc.date.issued | 2016-08 | |
dc.identifier.citation | Clin Microbiol Infect . 2016 Aug;22(8):739.e1-4 | es_ES |
dc.identifier.uri | http://hdl.handle.net/20.500.12105/10287 | |
dc.description.abstract | No field method exists for identifying asymptomatic individuals in areas where Leishmania infantum is endemic. This work reports that, 24 h after stimulating whole blood with soluble Leishmania antigen (SLA), plasma interferon-γ (IFN-γ) and interleukin-2 (IL-2) become significantly elevated in samples from asymptomatic individuals (n=47) compared with those from negative controls (n=50), all of them recruited from a blood bank. When compared with the reference test SLA-lymphoproliferative assay, IL-2 appears as a new, 100% sensitive and specific marker for asymptomatic individuals with a positive cellular response (compared with 100% and 84.78%, respectively, for IFN-γ). Further studies in other transmission areas and in other cohorts of exposed people need to be performed to confirm these results. Once validated, IFN-γ and IL-2 levels in SLA-stimulated whole blood could be reliably used in the field to estimate the prevalence of those asymptomatic individuals with Leishmania-specific cellular immune responses. | es_ES |
dc.description.sponsorship | We gratefully acknowledge the financial support of the Drugs for Neglected Diseases Initiative (DNDi) by the Department for International Development (DFID) , UK and the Swiss Agency for Development and Cooperation (SDC) , Swizerland; and of the Instituto de Salud Carlos III via the Tropical Diseases Research Network ( RICET RD12/0018/ 0003 and RD12/0018/0008 ) (www.ricet.es) and via the ISCIII-AES project ‘ Impact of a leishmaniasis outbreak in the southwest of Madrid in the immunosuppressed population ’ ( PI13/00440 ). EC was supported by a research contract funded via VII PN I+D+I 2013-2016 and FEDER Funds ( RICET RD12/ 0018/0003 ). | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | Elsevier | es_ES |
dc.type.hasVersion | AM | es_ES |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | * |
dc.subject.mesh | Asymptomatic Diseases | es_ES |
dc.subject.mesh | Leishmania infantum | es_ES |
dc.subject.mesh | Adult | es_ES |
dc.subject.mesh | Biomarkers | es_ES |
dc.subject.mesh | Cytokines | es_ES |
dc.subject.mesh | Female | es_ES |
dc.subject.mesh | Humans | es_ES |
dc.subject.mesh | Interleukin-2 | es_ES |
dc.subject.mesh | Leishmaniasis, Visceral | es_ES |
dc.subject.mesh | Male | es_ES |
dc.subject.mesh | Middle Aged | es_ES |
dc.subject.mesh | Young Adult | es_ES |
dc.title | Interleukin-2 as a marker for detecting asymptomatic individuals in areas where Leishmania infantum is endemic. | es_ES |
dc.type | journal article | es_ES |
dc.rights.license | Attribution-NonCommercial-NoDerivatives 4.0 Internacional | * |
dc.identifier.pubmedID | 27265372 | es_ES |
dc.format.volume | 22 | es_ES |
dc.format.number | 8 | es_ES |
dc.format.page | 739.e1-4 | es_ES |
dc.identifier.doi | 10.1016/j.cmi.2016.05.021 | es_ES |
dc.contributor.funder | Department for International Development (Reino Unido) | |
dc.contributor.funder | Instituto de Salud Carlos III | |
dc.contributor.funder | RETICS-Investigación colaborativa en Enfermedades Tropicales (RICET-ISCIII) (España) | |
dc.contributor.funder | Unión Europea. Fondo Europeo de Desarrollo Regional (FEDER/ERDF) | |
dc.description.peerreviewed | Sí | es_ES |
dc.identifier.e-issn | 1469-0691 | es_ES |
dc.relation.publisherversion | https://doi.org/10.1016/j.cmi.2016.05.021 | es_ES |
dc.identifier.journal | Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases | es_ES |
dc.repisalud.centro | ISCIII::Centro Nacional de Microbiología | es_ES |
dc.repisalud.institucion | ISCIII | es_ES |
dc.relation.projectID | info:eu_repo/grantAgreement/ES/RICET RD12/0018/ 0003 | es_ES |
dc.relation.projectID | info:eu_repo/grantAgreement/ES/RD12/0018/0008 | es_ES |
dc.relation.projectID | info:eu_repo/grantAgreement/ES/PI13/00440 | es_ES |
dc.relation.projectID | info:eu_repo/grantAgreement/ES/RICET RD12/ 0018/0003 | es_ES |
dc.rights.accessRights | open access | es_ES |